GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System ...

“Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...

GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY ® Vitreoretinal Cataract System (VCS) and UNITY ® ...

Investing.com -- BofA Securities cut Alcon to “underperform” from “buy” rating, and lowered its price objective to CHF60 from ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...

Alcon ALC unveiled results from time and motion studies demonstrating superior efficiency with the UNITY Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to the ...

TORONTO, July 08, 2025--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System (VCS) has received ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...